logo
Plus   Neg
Share
Email

Otonomy Q4 Loss Narrows

Otonomy, Inc. (OTIC), Monday reported fourth-quarter net loss of $12.8 million or $0.42 per share, narrower than last year's net loss of $18.8 million or $0.62 per share.

Product sales were $208 thousand, compared to $270 thousand last year.

Analysts polled by Thomson Reuters estimate loss of $0.48 per share and revenues of $110 thousand for the quarter. Analysts estimates typically exclude one-time items.

"Our accomplishments in 2018 have positioned the company for significant advancement in 2019 as we continue enrollment of our Phase 3 trial of OTIVIDEX in Ménière's disease, initiate Phase 1/2 clinical trials for OTO-313 in tinnitus and OTO-413 in hearing loss, and work towards delivering value-creating results for all three clinical trials in 2020," said David A. Weber, Ph.D., president and CEO of Otonomy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Monsanto on Thursday pleaded guilty to illegally using a banned pesticide known as Penncap-M on research crops at one of its facilities on the Hawaiian island of Maui. The agro-chemicals company will pay $10 million for charges that it unlawfully stored the banned pesticide, which had to be managed as an acute hazardous waste. The banned pesticide is specifically methyl parathion. Anti-aging skin care products, beauty serum ingredients and essential oils provider Resurrectionbeauty issued a recall for about 270 units of wintergreen essential oil due to risk of poisoning for young children if they swallow it. However, the company has not received reports of any incidents or injuries so far. The product contains the substance methyl salicylate. Microsoft has delayed the worldwide launch of its Surface Earbuds till Spring 2020. The $249 wireless earbuds were originally expected to launch this year. The delay is a setback in Microsoft's attempt to compete with Apple's latest earbuds, AirPods Pro, which has a new design and features active noise cancellation.
Follow RTT
>